Skip to main content

Gillies Hunter's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed May 19, 2023

Accession no.
0001415889-23-008425
Filed
May 19, 2023
Trade date
May 17, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $21.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gillies HunterCIK 0001868997Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 17, 2023Common StockMOption exerciseAcquired+1,090$1.74+$1,896.64,341Direct
May 17, 2023Common StockSSaleDisposed−1,090$19.59F3−$21,353.13,251Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 17, 2023Common StockMOption exerciseDisposed−1,090$0.00$019,018Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.50 to $19.665, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)